|
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, announced a strategic partnership with the Global RDH12 Alliance (the Alliance) to advance Opus’ gene therapy programme for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting key advocacy groups dedicated to RDH12-related IRDs, including: (i) “RDH12 Fund for Sight” in the US and (ii) “Eyes on the Future” in the UK.
This collaboration will accelerate development of OPGx-RDH12, Opus’ gene therapy programme targeting the RDH12 gene mutation for the potential treatment of Leber congenital amaurosis (RDH12-LCA). Leber congenital amaurosis (LCA) is a rare IRD that causes progressive vision loss and blindness, often beginning in early childhood. Patients with RDH12 mutations often have early visual acuity loss with retinal structural changes by two years of age.
Under the agreement, the Alliance will provide up to $1.6 million towards the development of the OPGx-RDH12 programme. The partnership also includes a risk-sharing structure and performance-based milestones. Together, the parties will co-develop the OPGx-RDH12 programme, including the clinical and regulatory strategy, with the goal of filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) by late 2025.
“Since founding the RDH12 Fund for Sight more than a decade ago, our goal has always been to bring a treatment to the RDH12-LCA community,” said Mathew Pletcher, Ph.D., Board member of the RDH12 Fund for Sight and father to a 19-year-old living with the condition. “This partnership represents a significant step forward. By combining our patient community’s unique, first-hand perspectives on RDH12-LCA and resources with Opus’ gene therapy expertise, we can accelerate the transition of this promising therapy out of the laboratory and into the clinic.”
Silvia Cerolini, CEO of Eyes on the Future and mother of an 11-year-old girl affected by RDH12-LCA, added, “We are racing against time as our children’s vision continues to deteriorate. Partnering with Opus to bring this gene therapy into the clinic is an incredibly meaningful milestone, and it shows what’s possible when patients and the industry work together. It brings us one step closer to our mission: helping our kids and our community see the world for longer.”
“Opus is pleased to work directly with the patient community in true partnership,” said George Magrath, CEO of Opus Genetics. “This collaboration is much more than a financial arrangement. We value each other’s insights, experience and connections as critical to a successful co-development of this gene therapy.”
Professor Jean Bennett, MD, PhD, Opus Genetics Scientific Advisor and Board of Directors member, added, “With the understanding of how gene therapy works and the preclinical evidence so far, we see a clear path for its application to RDH12-LCA. I want to thank everybody in the RDH12 community for their indispensable support to RDH12 research over the years. This partnership is a critical enabler to accelerate the path to bringing this therapy to all of those in need.”
RDH12-LCA is an ultra-rare form of childhood blindness affecting several thousand people globally. Mutations in the RDH12 gene impair protein function in the retina, leading to early visual decline, often with structural retinal changes by age two, and rapid progression during the second decade of life. OPGx-RDH12 uses an adeno-associated virus (AAV) vector to deliver a functional copy of the RDH12 gene directly to photoreceptors in the retina. “Preclinical studies in cell and mouse models have shown restoration of RDH12 activity and functional improvements,” said Professor Jean Bennett, MD, PhD, Opus Genetics scientific advisor and board of directors member.
The RDH12 Fund for Sight is a US-based not-for-profit organization that aims to bring together families with common concerns and worries, collect and distribute information about the form of LCA caused by RDH12, and, most importantly, ensure that significant funds are devoted to the study and development of treatments for LCA caused by RDH12.
Eyes on the Future is a UK-based non-for-profit organization supporting research into rare diseases and eye diseases with specific focus on RDH12 inherited retinal dystrophies.
Opus Genetics is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases.
|